Cargando…

RETRACTED ARTICLE: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma

Osteosarcoma (OS) is the most common primary malignant bone tumor. However, the therapeutic results of the advanced cases at the first visit were still extremely poor. Therefore, more effective therapeutic options based on molecular profiling of OS are needed. In this study, we investigated the func...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasa, Keita, Saito, Tsuyoshi, Kurihara, Taisei, Hasegawa, Nobuhiko, Sano, Kei, Kubota, Daisuke, Akaike, Keisuke, Okubo, Taketo, Hayashi, Takuo, Takagi, Tatsuya, Yao, Takashi, Ishijima, Muneaki, Suehara, Yoshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777567/
https://www.ncbi.nlm.nih.gov/pubmed/35201455
http://dx.doi.org/10.1007/s12672-021-00453-2
_version_ 1784637096825192448
author Sasa, Keita
Saito, Tsuyoshi
Kurihara, Taisei
Hasegawa, Nobuhiko
Sano, Kei
Kubota, Daisuke
Akaike, Keisuke
Okubo, Taketo
Hayashi, Takuo
Takagi, Tatsuya
Yao, Takashi
Ishijima, Muneaki
Suehara, Yoshiyuki
author_facet Sasa, Keita
Saito, Tsuyoshi
Kurihara, Taisei
Hasegawa, Nobuhiko
Sano, Kei
Kubota, Daisuke
Akaike, Keisuke
Okubo, Taketo
Hayashi, Takuo
Takagi, Tatsuya
Yao, Takashi
Ishijima, Muneaki
Suehara, Yoshiyuki
author_sort Sasa, Keita
collection PubMed
description Osteosarcoma (OS) is the most common primary malignant bone tumor. However, the therapeutic results of the advanced cases at the first visit were still extremely poor. Therefore, more effective therapeutic options based on molecular profiling of OS are needed. In this study, we investigated the functions of endoplasmic reticulum (ER) stress activities in OS and elucidated whether ER stress inhibitors could exert antitumor effects. The expression of 84 key genes associated with unfolded protein response (UPR) was assessed in four OS cells (143B, MG63, U2OS and KHOS) by RT2 Profiler PCR Arrays. Based on results, we performed both siRNA and inhibitor assays focusing on IRE1α-XBP1 and PERK pathways. All OS cell lines showed resistance to PERK inhibitors. Furthermore, ATF4 and EIF2A inhibition by siRNA did not affect the survival of OS cell lines. On the other hand, IRE1α-XBP1 inhibition by toyocamycin suppressed OS cell growth (IC50: < 0.075 μM) and cell viability was suppressed in all OS cell lines by silencing XBP1 expression. The expression of XBP1s and XBP1u in OS cell lines and OS surgical samples were confirmed using qPCR. In MG63 and U2OS, toyocamycin decreased the expression level of XBP1s induced by tunicamycin. On the other hand, in 143B and KHOS, stimulation by toyocamycin did not clearly change the expression level of XBP1s induced by tunicamycin. However, morphological apoptotic changes and caspase activation were observed in these two cell lines. Inhibition of the IRE1α-XBP1s pathway is expected to be a promising new target for OS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-021-00453-2.
format Online
Article
Text
id pubmed-8777567
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-87775672022-02-03 RETRACTED ARTICLE: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma Sasa, Keita Saito, Tsuyoshi Kurihara, Taisei Hasegawa, Nobuhiko Sano, Kei Kubota, Daisuke Akaike, Keisuke Okubo, Taketo Hayashi, Takuo Takagi, Tatsuya Yao, Takashi Ishijima, Muneaki Suehara, Yoshiyuki Discov Oncol Research Osteosarcoma (OS) is the most common primary malignant bone tumor. However, the therapeutic results of the advanced cases at the first visit were still extremely poor. Therefore, more effective therapeutic options based on molecular profiling of OS are needed. In this study, we investigated the functions of endoplasmic reticulum (ER) stress activities in OS and elucidated whether ER stress inhibitors could exert antitumor effects. The expression of 84 key genes associated with unfolded protein response (UPR) was assessed in four OS cells (143B, MG63, U2OS and KHOS) by RT2 Profiler PCR Arrays. Based on results, we performed both siRNA and inhibitor assays focusing on IRE1α-XBP1 and PERK pathways. All OS cell lines showed resistance to PERK inhibitors. Furthermore, ATF4 and EIF2A inhibition by siRNA did not affect the survival of OS cell lines. On the other hand, IRE1α-XBP1 inhibition by toyocamycin suppressed OS cell growth (IC50: < 0.075 μM) and cell viability was suppressed in all OS cell lines by silencing XBP1 expression. The expression of XBP1s and XBP1u in OS cell lines and OS surgical samples were confirmed using qPCR. In MG63 and U2OS, toyocamycin decreased the expression level of XBP1s induced by tunicamycin. On the other hand, in 143B and KHOS, stimulation by toyocamycin did not clearly change the expression level of XBP1s induced by tunicamycin. However, morphological apoptotic changes and caspase activation were observed in these two cell lines. Inhibition of the IRE1α-XBP1s pathway is expected to be a promising new target for OS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-021-00453-2. Springer US 2021-11-30 /pmc/articles/PMC8777567/ /pubmed/35201455 http://dx.doi.org/10.1007/s12672-021-00453-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Sasa, Keita
Saito, Tsuyoshi
Kurihara, Taisei
Hasegawa, Nobuhiko
Sano, Kei
Kubota, Daisuke
Akaike, Keisuke
Okubo, Taketo
Hayashi, Takuo
Takagi, Tatsuya
Yao, Takashi
Ishijima, Muneaki
Suehara, Yoshiyuki
RETRACTED ARTICLE: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma
title RETRACTED ARTICLE: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma
title_full RETRACTED ARTICLE: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma
title_fullStr RETRACTED ARTICLE: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma
title_full_unstemmed RETRACTED ARTICLE: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma
title_short RETRACTED ARTICLE: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma
title_sort retracted article: ire1α-xbp1 but not perk inhibition exerts anti-tumor activity in osteosarcoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777567/
https://www.ncbi.nlm.nih.gov/pubmed/35201455
http://dx.doi.org/10.1007/s12672-021-00453-2
work_keys_str_mv AT sasakeita retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma
AT saitotsuyoshi retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma
AT kuriharataisei retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma
AT hasegawanobuhiko retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma
AT sanokei retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma
AT kubotadaisuke retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma
AT akaikekeisuke retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma
AT okubotaketo retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma
AT hayashitakuo retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma
AT takagitatsuya retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma
AT yaotakashi retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma
AT ishijimamuneaki retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma
AT sueharayoshiyuki retractedarticleire1axbp1butnotperkinhibitionexertsantitumoractivityinosteosarcoma